JP4353798B2 - 肝細胞癌に関連する遺伝子およびタンパク質 - Google Patents

肝細胞癌に関連する遺伝子およびタンパク質 Download PDF

Info

Publication number
JP4353798B2
JP4353798B2 JP2003530730A JP2003530730A JP4353798B2 JP 4353798 B2 JP4353798 B2 JP 4353798B2 JP 2003530730 A JP2003530730 A JP 2003530730A JP 2003530730 A JP2003530730 A JP 2003530730A JP 4353798 B2 JP4353798 B2 JP 4353798B2
Authority
JP
Japan
Prior art keywords
protein
znfn3a1
dna
seq
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003530730A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005511023A (ja
JP2005511023A5 (enExample
Inventor
祐輔 中村
洋一 古川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA 2399569 external-priority patent/CA2399569A1/en
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of JP2005511023A publication Critical patent/JP2005511023A/ja
Publication of JP2005511023A5 publication Critical patent/JP2005511023A5/ja
Application granted granted Critical
Publication of JP4353798B2 publication Critical patent/JP4353798B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2003530730A 2001-09-25 2002-09-25 肝細胞癌に関連する遺伝子およびタンパク質 Expired - Fee Related JP4353798B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32426101P 2001-09-25 2001-09-25
US39166602P 2002-06-26 2002-06-26
CA 2399569 CA2399569A1 (en) 2001-09-25 2002-08-23 Diagnostic markers and drug targets for treatment of cancer
PCT/JP2002/009876 WO2003027143A2 (en) 2001-09-25 2002-09-25 Gene and protein relating to hepatocellular carcinoma

Publications (3)

Publication Number Publication Date
JP2005511023A JP2005511023A (ja) 2005-04-28
JP2005511023A5 JP2005511023A5 (enExample) 2006-01-05
JP4353798B2 true JP4353798B2 (ja) 2009-10-28

Family

ID=27171637

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003530730A Expired - Fee Related JP4353798B2 (ja) 2001-09-25 2002-09-25 肝細胞癌に関連する遺伝子およびタンパク質

Country Status (9)

Country Link
US (3) US7767392B2 (enExample)
EP (1) EP1430152B1 (enExample)
JP (1) JP4353798B2 (enExample)
CN (1) CN1628179B (enExample)
AT (1) ATE356223T1 (enExample)
AU (1) AU2002329061A1 (enExample)
DE (1) DE60218710T2 (enExample)
ES (1) ES2283592T3 (enExample)
WO (1) WO2003027143A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2399569A1 (en) 2001-09-25 2003-03-25 Yusuke Nakamura Diagnostic markers and drug targets for treatment of cancer
ES2283592T3 (es) 2001-09-25 2007-11-01 Oncotherapy Science, Inc. Gen y proteina relacionados con el carcinoma hepatocelular.
DE602004032114D1 (de) * 2003-02-28 2011-05-19 Oncotherapy Science Inc Rna-interferenz für das gen znfn3a1 als verfahren zur hemmung des wachstums von krebszellen
JP2007506425A (ja) * 2003-09-24 2007-03-22 オンコセラピー・サイエンス株式会社 肝細胞癌を診断する方法
TWI350373B (en) * 2004-01-23 2011-10-11 Oncotherapy Science Inc Methods of detecting methyl transferase activity and methods of screening formethyl transferase activity modulators
US20060189560A1 (en) * 2005-01-27 2006-08-24 Ajit Kumar Molecular method to augment RNA mediated gene silencing
US7939254B2 (en) * 2005-02-28 2011-05-10 Oncotherapy Science, Inc. Breast cancer related gene ZNFN3A1
WO2006121208A1 (en) * 2005-05-12 2006-11-16 Oncotherapy Science, Inc. Polymorphisms of the e2f-1 binding element and methods of determining cancer susceptibility
TW200741009A (en) * 2005-07-01 2007-11-01 Oncotherapy Science Inc Methods of modulating SMYD3 for treatment of cancer
US8354223B2 (en) 2007-06-14 2013-01-15 Oncotherapy Science, Inc. Methods of identifying agents that modulate methylation of VEGFR1 by SMYD3
EP2405269B8 (en) 2009-03-05 2016-10-12 National Institute of Advanced Industrial Science And Technology Method for detecting and distinguishing intrahepatic cholangiocarcinoma
US20110021362A1 (en) * 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
US20140308678A1 (en) 2011-12-02 2014-10-16 Oncotherapy Science, Inc. Smyd2 as a target gene for cancer therapy and diagnosis
WO2014141652A1 (en) * 2013-03-11 2014-09-18 Oncotherapy Science, Inc. Smyd3 peptides and vaccines containing the same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999039200A1 (en) 1998-01-29 1999-08-05 Thomas Jefferson University Molecular markers for diagnosing hepatocellular carcinoma
US6783961B1 (en) * 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
WO2000017355A2 (en) 1998-09-18 2000-03-30 Incyte Pharmaceuticals, Inc. Human cytoskeleton associated proteins
AU2743400A (en) * 1999-01-29 2000-08-18 Incyte Pharmaceuticals, Inc. Nucleic-acid binding proteins
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
WO2001029221A2 (en) 1999-10-20 2001-04-26 Zymogenetics, Inc. Proteins and polynucleotides encoding them
AU783762B2 (en) 1999-12-23 2005-12-01 Arca Biopharma, Inc. Methods and materials relating to prothrombinase-like polypeptides and polynucleotides
EP1591448A3 (en) 2000-04-18 2006-01-11 Nuvelo, Inc. Novel nucleic acids and polypeptides
MXPA03006617A (es) 2001-01-24 2004-12-02 Protein Design Labs Inc Metodos de diagnostico de cancer de pecho, composiciones y metodos de rastreo de moduladores de cancer de pecho.
GB0111218D0 (en) 2001-05-08 2001-06-27 Cancer Res Ventures Ltd Assays methods and means
WO2002092002A2 (en) 2001-05-11 2002-11-21 The Burnham Institute Screening, diagnostic and therapeutic methods relating to riz
CA2454183C (en) 2001-07-23 2016-09-06 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for rnai mediated inhibition of gene expression in mammals
ES2283592T3 (es) * 2001-09-25 2007-11-01 Oncotherapy Science, Inc. Gen y proteina relacionados con el carcinoma hepatocelular.
CA2399569A1 (en) 2001-09-25 2003-03-25 Yusuke Nakamura Diagnostic markers and drug targets for treatment of cancer
EP1453532A4 (en) * 2001-12-13 2007-03-28 Exelixis Inc TAOJIKS AS MODIFICATORS OF THE BETA-CATENIN PATH AND METHOD OF USE
DE602004032114D1 (de) 2003-02-28 2011-05-19 Oncotherapy Science Inc Rna-interferenz für das gen znfn3a1 als verfahren zur hemmung des wachstums von krebszellen
TWI350373B (en) * 2004-01-23 2011-10-11 Oncotherapy Science Inc Methods of detecting methyl transferase activity and methods of screening formethyl transferase activity modulators
US7939254B2 (en) * 2005-02-28 2011-05-10 Oncotherapy Science, Inc. Breast cancer related gene ZNFN3A1
TW200741009A (en) * 2005-07-01 2007-11-01 Oncotherapy Science Inc Methods of modulating SMYD3 for treatment of cancer
US8354223B2 (en) 2007-06-14 2013-01-15 Oncotherapy Science, Inc. Methods of identifying agents that modulate methylation of VEGFR1 by SMYD3

Also Published As

Publication number Publication date
DE60218710T2 (de) 2007-12-06
ATE356223T1 (de) 2007-03-15
CN1628179A (zh) 2005-06-15
WO2003027143A2 (en) 2003-04-03
EP1430152B1 (en) 2007-03-07
US20100248240A1 (en) 2010-09-30
DE60218710D1 (de) 2007-04-19
JP2005511023A (ja) 2005-04-28
ES2283592T3 (es) 2007-11-01
US8148080B2 (en) 2012-04-03
EP1430152A2 (en) 2004-06-23
WO2003027143A3 (en) 2003-10-30
CN1628179B (zh) 2011-04-20
US7767392B2 (en) 2010-08-03
AU2002329061A1 (en) 2003-04-07
US20120149762A1 (en) 2012-06-14
US20040235018A1 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
US8124341B2 (en) Genes and polypeptides relating to hepatocellular or colorectal carcinoma
US8148080B2 (en) Gene and protein relating to hepatocellular carcinoma and methods of use thereof
US8242245B2 (en) Fetal polypeptides from human liver
JP4499926B2 (ja) 腫瘍抑制遺伝子
US8058408B2 (en) Transcription factor having zinc finger domains
EP1215283A1 (en) NOVEL bHLH TYPE TRANSCRIPTION FACTOR GENE DEC2
CN100497624C (zh) Wt1相互作用蛋白质wtip
US20030157501A1 (en) Novel human rna helicase, helicain
JP2005521421A (ja) 結腸直腸癌を診断および治療する方法
HK1050219A (en) Wt1-interacting protein wtip
JP2004267003A (ja) ヒト白血球型抗原領域に存在する新規遺伝子

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050705

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050705

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20070905

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20071031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090722

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090728

R150 Certificate of patent or registration of utility model

Ref document number: 4353798

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120807

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120807

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120807

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120807

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120807

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130807

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130807

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees